BioCorRx Inc. (OTCQB: BICX), a developer of treatment programs for substance abuse and related disorders, announced its common stock will transition from the OTCQB Venture Market to the OTCID Market due to a technical eligibility matter related to public float requirements. The company emphasized this transition does not result from any delinquency in its Securities and Exchange Commission reporting obligations and that it remains current with all periodic reporting requirements.
The OTCID Market was launched by OTC Markets Group in July 2025 as part of structural updates to U.S. over-the-counter equity markets, replacing the former Pink "Current Information" category with a baseline disclosure market for issuers that publish current information and provide management certification. BioCorRx, which has been a fully reporting public company for approximately 14 years, stated it intends to maintain a high level of transparency with shareholders despite the market tier change.
To address the public float requirement and support eligibility to regain quotation on the OTCQB Venture Market, BioCorRx plans to file a Form S-1 resale registration statement with the SEC. The company clarified it does not expect to raise capital or receive any proceeds from this filing, noting there can be no assurance the registration statement will be declared effective or that the company will regain or maintain OTCQB quotation.
BioCorRx does not anticipate any change to its business operations or SEC reporting obligations as a result of the quotation tier transition. Shareholders may continue to access the company's SEC filings on the SEC's website at https://www.sec.gov, with no expected interruption in reporting or availability of public disclosures.
The company's treatment programs include Beat Addiction Recovery, which combines proprietary Cognitive Behavioral Therapy modules with peer support via mobile app and physician-prescribed medication, and the UnCraveRx Weight Loss Program, which offers medication-assisted weight loss with access to wellness specialists. More information on UnCraveRx is available at https://www.uncraverx.com.
Through its subsidiary BioCorRx Pharmaceuticals Inc., the company focuses on pharmaceutical commercialization and development, including LUCEMYRA (lofexidine), an FDA-approved medication for mitigating opioid withdrawal symptoms in adults, and BICX104, an investigational implantable naltrexone pellet program. Additional information about the company and its subsidiary pipeline can be found at https://www.BioCorRx.com.
This market transition matters because it highlights the regulatory complexities facing healthcare companies in public markets while they address significant public health challenges. BioCorRx operates in critical treatment areas including substance use disorders and obesity, with the National Institute on Drug Abuse supporting BICX104 research under Award Number U01DA059994. The company's work addresses conditions affecting millions globally, with methamphetamine use disorder impacting over 16.6 million people according to the 2022 National Survey on Drug Use and Health, and obesity affecting an estimated 1 billion people worldwide according to World Health Organization data.
The planned Form S-1 filing represents a strategic move to maintain market accessibility while continuing development of treatments for opioid use disorder, a chronic condition associated with increased morbidity and mortality rates. As healthcare costs related to obesity are projected to reach $4 trillion by 2035 affecting over 4 billion people, companies like BioCorRx that develop integrated treatment approaches play an increasingly important role in addressing these global health challenges.
